HUP0402068A2 - Benzotriazepinek mint gasztrin és kolecisztokinin receptor ligandumok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények - Google Patents
Benzotriazepinek mint gasztrin és kolecisztokinin receptor ligandumok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0402068A2 HUP0402068A2 HU0402068A HUP0402068A HUP0402068A2 HU P0402068 A2 HUP0402068 A2 HU P0402068A2 HU 0402068 A HU0402068 A HU 0402068A HU P0402068 A HUP0402068 A HU P0402068A HU P0402068 A2 HUP0402068 A2 HU P0402068A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- compounds
- alkyl
- formula
- nhc
- Prior art date
Links
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- QVWKODLMAFCGLB-UHFFFAOYSA-N 1H-1,2,3-benzotriazepine Chemical class N1N=NC=CC2=CC=CC=C12 QVWKODLMAFCGLB-UHFFFAOYSA-N 0.000 title 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 title 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 title 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 title 1
- 102000052874 Gastrin receptors Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 amino - Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 102100021022 Gastrin Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya az (I) általános képletű vegyületek alkalmazása -ahol a képletben W jelentése N vagy N+-O-; R1 és R5 jelentéseegymástól függetlenül hidrogénatom, alkil-, alkoxi-, tio-, alkiltio-,karboxil-, karboxialkil-, formil-, alkilkarbonil-, alkiloxikarbonil-,alkilkarboniloxi-, nitro-, trihalometil-, hidroxil-, hidroxialkil-,amino-, alkilamino-, dialkilamino-, aminokarbonil-csoport,halogénatom, haloalkil-, aminoszulfonil-, alkilszulfonilamino-,alkilaminokarbonil-, dialkilaminokarbonil-,[N-Z]alkilkarbonil-amino-,formiloxi-, formamido-, alkilaminoszulfonil-, dialkilaminoszulfonil-,[N-Z]alkilszulfonilamino- vagy cianocsoport; vagy R1 és R5 együttmetiléndioxicsoportot képez; R2 jelentése hidrogénatom vagy adottesetben szubsztituált szénhidrogéncsoport, ahol legfeljebb háromszénatom adott esetben fel lehet cserélve nitrogén-, oxigén- és/vagykénatommal; R3 jelentése -(CR11R12)m-X- (CR13R14)P-R9 általánosképletű csoport; m értéke 0, 1, 2, 3 vagy 4; p értéke 0, 1 vagy 2; Xjelentése kémaiai kötés, -CR15=CR16-, -C=C-, C(O)NH, NHC(O), C(O)NMe,NMeC(O), C(O)O, NHC(O)NH, NHC(O)O, OC(O)NH, NH, O, CO, SO2, SO2NH,C(O)NHNH, (a) vagy (b) képletű csoport; R9 jelentése hidrogénatom,alkilcsoport; vagy adott esetben szubsztituált fenil-, naftil-,piridil-, benzimidazolil-, indazolil-, kinolinil-, izokinolinil-,tetrahidroizokinolinil-, indolinil-, izoindolinil-, indolil-,izoindolil vagy 2-piridonicsoport, Z jelentése hidrogénatom, 1-6szénatomos alkil-, terc-butoxikarbonil-, acetil-, benzoil- vagybenzilcsoport; R9 jelentése adott esetben szubsztituáltszénhidrogéncsoport, amelyben legfeljebb három szénatom adott esetbenfel lehet cserélni nitrogén-, oxigén- és/vagy kénatommal; R11, Rl2,R13, Rl4, Rl5, Rl7, R18 és R19 jelentése egymástól függetlenülhidrogénatom vagy alkilcsoport; és R16 jelentése hidrogénatom, alkil-vagy acetilaminocsoport; gasztrinnal kapcsolatos rendellenességekkezelésében történő alkalmazásra. A találmány tárgyát képezik továbbáa vegyületeket tartalmazó gyógyászati készítmények, az (I) általánosképletű vegyületek szűkebb körét képező (IIa) és (IIb) vegyületek éseljárások a vegyületek és a készítmények előállítására. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0127262A GB0127262D0 (en) | 2001-11-13 | 2001-11-13 | Gastrin and cholecystokinin receptor ligands (VI) |
| GB0219051A GB0219051D0 (en) | 2002-08-15 | 2002-08-15 | Gastrin and cholecystokinin receptor ligands (V1-2) |
| PCT/GB2002/005121 WO2003041714A1 (en) | 2001-11-13 | 2002-11-12 | Benzotriazepines as gastrin and cholecystokinin receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402068A2 true HUP0402068A2 (hu) | 2005-02-28 |
| HUP0402068A3 HUP0402068A3 (en) | 2005-09-28 |
Family
ID=26246762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402068A HUP0402068A3 (en) | 2001-11-13 | 2002-11-12 | Benzotriazepines as gastrin and cholecystokinin receptor ligands, process for their preparation and pharmaceutical compositions containing them |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060003993A1 (hu) |
| EP (1) | EP1443934B1 (hu) |
| JP (1) | JP2005513013A (hu) |
| KR (1) | KR20050044852A (hu) |
| CN (1) | CN100348196C (hu) |
| AR (1) | AR037359A1 (hu) |
| AT (1) | ATE293449T1 (hu) |
| BR (1) | BR0213317A (hu) |
| CA (1) | CA2466955A1 (hu) |
| DE (1) | DE60203818T2 (hu) |
| ES (1) | ES2240815T3 (hu) |
| HU (1) | HUP0402068A3 (hu) |
| IL (1) | IL161330A0 (hu) |
| MX (1) | MXPA04003544A (hu) |
| NO (1) | NO20042452L (hu) |
| NZ (1) | NZ532213A (hu) |
| PL (1) | PL369568A1 (hu) |
| RU (1) | RU2304438C2 (hu) |
| TW (1) | TW200303205A (hu) |
| WO (1) | WO2003041714A1 (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004101533A1 (en) * | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
| WO2005018640A1 (en) * | 2003-08-20 | 2005-03-03 | The Procter & Gamble Company | Kit for treatment of upper gastrointestinal tract conditions |
| WO2005074931A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations comprising (s) -pantoprazole |
| GB0425196D0 (en) * | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| EP1948624B1 (en) | 2005-09-16 | 2013-10-23 | Janssen Pharmaceutica N.V. | Process for the preparation of benzo[e][1,2,4]triazepin-2-one derivatives |
| GB0610018D0 (en) * | 2006-05-19 | 2006-06-28 | James Black Foundation | Benzotriazepinone derivatives |
| WO2007135417A1 (en) * | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| US7863330B2 (en) | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
| KR102254957B1 (ko) | 2013-11-22 | 2021-05-25 | 씨엘 바이오사이언시즈 엘엘씨 | 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드) |
| GB201414116D0 (en) | 2014-08-08 | 2014-09-24 | Trio Medicines Ltd | Benzodiazepine derivatives |
| GB201513979D0 (en) | 2015-08-07 | 2015-09-23 | Trio Medicines Ltd | Synthesis of benzodiazepine derivatives |
| US11097031B2 (en) | 2016-08-01 | 2021-08-24 | The Procter & Gamble Company | Phase-stable, sprayable freshening compositions comprising suspended particles |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3176008A (en) * | 1962-09-11 | 1965-03-30 | American Home Prod | 5-phenyl-benzotriazepin-2-one compounds and their production |
| US5091381A (en) * | 1991-04-12 | 1992-02-25 | Biomeasure, Inc. | 2H-1,3,4-benzotriazepin-2-ones |
| WO1993012817A1 (en) * | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| US5378838A (en) * | 1993-01-13 | 1995-01-03 | Merck & Co., Inc. | Benzodiazepine cholecystokinin antagonists |
-
2002
- 2002-11-12 BR BR0213317-2A patent/BR0213317A/pt not_active Application Discontinuation
- 2002-11-12 AT AT02775003T patent/ATE293449T1/de not_active IP Right Cessation
- 2002-11-12 NZ NZ532213A patent/NZ532213A/en unknown
- 2002-11-12 RU RU2004117880/15A patent/RU2304438C2/ru not_active IP Right Cessation
- 2002-11-12 WO PCT/GB2002/005121 patent/WO2003041714A1/en active IP Right Grant
- 2002-11-12 JP JP2003543601A patent/JP2005513013A/ja active Pending
- 2002-11-12 IL IL16133002A patent/IL161330A0/xx unknown
- 2002-11-12 MX MXPA04003544A patent/MXPA04003544A/es unknown
- 2002-11-12 ES ES02775003T patent/ES2240815T3/es not_active Expired - Lifetime
- 2002-11-12 KR KR1020047007006A patent/KR20050044852A/ko not_active Application Discontinuation
- 2002-11-12 US US10/495,464 patent/US20060003993A1/en not_active Abandoned
- 2002-11-12 DE DE60203818T patent/DE60203818T2/de not_active Expired - Fee Related
- 2002-11-12 CN CNB028223403A patent/CN100348196C/zh not_active Expired - Fee Related
- 2002-11-12 PL PL02369568A patent/PL369568A1/xx not_active Application Discontinuation
- 2002-11-12 EP EP02775003A patent/EP1443934B1/en not_active Expired - Lifetime
- 2002-11-12 CA CA002466955A patent/CA2466955A1/en not_active Abandoned
- 2002-11-12 HU HU0402068A patent/HUP0402068A3/hu unknown
- 2002-11-13 AR ARP020104345A patent/AR037359A1/es unknown
- 2002-11-13 TW TW091133267A patent/TW200303205A/zh unknown
-
2004
- 2004-06-11 NO NO20042452A patent/NO20042452L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1443934B1 (en) | 2005-04-20 |
| PL369568A1 (en) | 2005-05-02 |
| EP1443934A1 (en) | 2004-08-11 |
| CN1585643A (zh) | 2005-02-23 |
| JP2005513013A (ja) | 2005-05-12 |
| US20060003993A1 (en) | 2006-01-05 |
| TW200303205A (en) | 2003-09-01 |
| HUP0402068A3 (en) | 2005-09-28 |
| IL161330A0 (en) | 2004-09-27 |
| CN100348196C (zh) | 2007-11-14 |
| RU2304438C2 (ru) | 2007-08-20 |
| BR0213317A (pt) | 2004-10-13 |
| AU2002341218B2 (en) | 2007-03-15 |
| ATE293449T1 (de) | 2005-05-15 |
| NO20042452L (no) | 2004-08-12 |
| KR20050044852A (ko) | 2005-05-13 |
| RU2004117880A (ru) | 2005-04-20 |
| DE60203818D1 (de) | 2005-05-25 |
| ES2240815T3 (es) | 2005-10-16 |
| DE60203818T2 (de) | 2006-01-26 |
| AR037359A1 (es) | 2004-11-03 |
| MXPA04003544A (es) | 2004-07-22 |
| NZ532213A (en) | 2006-12-22 |
| CA2466955A1 (en) | 2003-05-22 |
| WO2003041714A1 (en) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402068A2 (hu) | Benzotriazepinek mint gasztrin és kolecisztokinin receptor ligandumok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
| NO983707L (no) | Kinazolin-derivater som antitumor-midler | |
| MY116761A (en) | Novel spiroazabicyclic heterocyclic compounds. | |
| MY136240A (en) | Quinuclidine acrylamides | |
| ATE442362T1 (de) | Pyridylcyanoguanidin verbindungen | |
| DE69915519D1 (en) | Pyrazolopyridine | |
| AR018031A1 (es) | Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la manufactura de un medicamento | |
| TR200001279T2 (tr) | Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler. | |
| DK1381366T3 (da) | Indol, azaindol og beslægtede heterocykliske amidopiperazinderivater | |
| YU10900A (sh) | 2-aminopiridini koji sadrže supstituente sa fuzionisanim prstenovima kao nos inhibitori | |
| HUP0301069A2 (hu) | Új biaril-karboxamidok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0402640A2 (hu) | Indolilalkilamin-származékok 5-hidroxitriptamin-6 ligandumokként, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
| HUP0400467A2 (hu) | 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0402458A2 (hu) | Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek | |
| HUP0303729A2 (hu) | Akridinszármazékok és azok gyógyszerként történő alkalmazása és eljárás az előállításukra | |
| HUP9901590A2 (hu) | Szubsztituált aza- és diaza-cikloheptán- és -ciklooktán-származékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP9901613A2 (hu) | Szubsztituált tetraciklusos kondenzált furán-amin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002921A2 (hu) | Sejt proliferációs inhibitor hatású ciano-guanidin-származékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| AU2003226724A8 (en) | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands | |
| HUP9901685A2 (hu) | Kolchicinszármazékok és azokat tartalmazó gyógyászati készítmények | |
| HUP0400465A2 (hu) | Kortikotropin-feloldó faktor (CRF) receptor antagonista biciklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203839A2 (hu) | 4-Fenil-1-piperazinil-, -piperidinil- és tetrahidropiridil-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203976A2 (hu) | Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MY141583A (en) | Novel fused heterocycles and uses thereof |